Royal Bank of Canada boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,150,802 shares of the company’s stock after acquiring an additional 23,678 shares during the quarter. Royal Bank of Canada’s holdings in Novo Nordisk A/S were worth $49,358,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Proficio Capital Partners LLC raised its position in Novo Nordisk A/S by 155.6% during the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after acquiring an additional 1,505 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Novo Nordisk A/S by 167.8% during the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after acquiring an additional 1,918 shares in the last quarter. AlphaMark Advisors LLC raised its position in Novo Nordisk A/S by 1.1% during the second quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after acquiring an additional 30 shares in the last quarter. Parallel Advisors LLC raised its position in Novo Nordisk A/S by 120.3% during the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after acquiring an additional 1,553 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in Novo Nordisk A/S by 3,609.0% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,709 shares of the company’s stock worth $127,000 after acquiring an additional 3,609 shares in the last quarter. 6.01% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Novo Nordisk A/S (NYSE:NVO) traded down 0.41% during trading on Thursday, hitting $49.08. 97,987 shares of the stock traded hands. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $49.50. The stock has a 50 day moving average price of $47.65 and a 200-day moving average price of $42.27. The stock has a market cap of $121.73 billion, a price-to-earnings ratio of 19.74 and a beta of 0.61.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/05/royal-bank-of-canada-has-49-36-million-holdings-in-novo-nordisk-as-nvo.html.

Several research firms have issued reports on NVO. BidaskClub raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. BNP Paribas lowered shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Zacks Investment Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Tuesday, September 19th. Finally, Bank of America Corporation raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $55.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.